Abstract
Thymidine phosphorylase (TP) is an enzyme that acts as a proangiogenic factor. Overexpression of the enzyme was observed in various solid tumors and several chronic inflammatory diseases, where it was correlated with level of angiogenesis and elevated progression of the disease. TP inhibitors are compounds designed to interfere with the processes connected with catalytic function of this enzyme including TP-mediated angiogenesis and the degradation of important antiviral and anticancer drugs. This chapter comprehensively reviews the hitherto known TP inhibitors with further insight into their potential applications in the clinical practices.
Keywords: Thymidine phosphorylase, angiogenesis, platelet-derived endothelial cell growth factor, gliostatin, cancer chemotherapy, thymidine phosphorylase inhibitors.
Related Journals
Current Drug Safety
Inflammation & Allergy - Drug Targets (Discontinued)
Recent Patents on Anti-Infective Drug Discovery
Current Drug Discovery Technologies
Current Drug Targets - Inflammation & Allergy
Current Bioactive Compounds
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Anti-Cancer Agents in Medicinal Chemistry
Current Drug Targets
Letters in Drug Design & Discovery
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Angiogenesis & Therapeutic Targets In Cancer
Biopolymers In Drug Delivery: Recent Advances and Challenges
Chemoinformatics: Directions Toward Combating Neglected Diseases
Current Advances in Drug Delivery Through Fast Dissolving/Disintegrating Dosage Forms
Current Technologies To Increase The Transdermal Delivery Of Drugs
Current Technologies To Increase The Transdermal Delivery Of Drugs